Actively Recruiting
Phase 3 Study Comparing Velzatinib and Imatinib for Adults With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors
Led by GlaxoSmithKline · Updated on 2026-10-23
800
Participants Needed
93
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Gastrointestinal Stromal Tumor GIST is a type of soft tissue tumor that forms in the digestive system, often in the stomach or small intestine, caused by changes in certain proteins leading to uncontrolled cell growth. This research is evaluating the drug velzatinib GSK6042981 in adults with newly diagnosed metastatic or unresectable GIST, comparing it to the standard treatment imatinib to see if it can delay disease progression and assess safety and tolerability. Participants will be randomly assigned to receive either velzatinib or imatinib, with treatments given according to study protocols. The study will monitor each participant over time to compare the effects of these medications on tumor growth and patient health. Throughout the trial, participants will undergo regular assessments including imaging scans reviewed by independent central review, evaluations of tumor response, survival tracking, safety monitoring of side effects and vital signs, and quality of life questionnaires. The study will last for up to approximately 74 to 75 months, with ongoing evaluations to measure progression-free survival and other important outcomes.
CONDITIONS
Brief Title
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here